AI4CMR v1.0
AI4MedImaging Medical Solutions S.A. • Radiology • 07/22/2022
Device Purpose
AI4CMR v1.0 is a cloud-hosted artificial intelligence software designed to automatically segment cardiac structures from MR images and quantify key ventricular function metrics like volumes and ejection fraction. Its purpose is to provide quantitative data to assist clinicians, leveraging an AI model trained on cardiac MR cases and validated against expert readers, though its output is not intended for standalone diagnostic use.
Summary
AI4CMR v1.0 is a software designed to assist in the analysis of cardiac function by processing magnetic resonance (MR) images from 1.5T and 3T scanners. It operates as a cloud-hosted service, functioning as a plug-in within a user's existing DICOM viewer application, which also serves as the user interface. The core methodology involves leveraging artificial intelligence to automatically segment cardiac structures, specifically the left and right ventricles, and quantify various functional measurements. These measurements include ventricle volumes (end-diastolic and end-systolic), ejection fraction, stroke volume, cardiac output, and left ventricular myocardial mass, along with their indexed counterparts if patient height and weight are available. The AI model was trained on a dataset of 824 anonymized cardiac MR cases acquired from a Siemens system. The performance of AI4CMR v1.0 was evaluated through bench testing and a multi-reader multi-center (MRMC) clinical study. Bench testing against the SCMR Consensus Contour Data (15 cases from Siemens, GE, Philips scanners) demonstrated an average Dice Similarity Coefficient (DSC) of 0.72 for myocardium segmentation. The MRMC study involved 146 CMR cases from Siemens, GE, and Philips 1.5T scanners, comparing the software's outputs against manual segmentations by two expert readers. Key performance metrics showed good agreement: for Left Ventricular Ejection Fraction, the software had a bias of 3.87% (standard deviation 5.74%) and an Intraclass Correlation Coefficient (ICC) of 0.96. For Right Ventricular Ejection Fraction, the bias was 7.80% (standard deviation 7.32%) with an ICC of 0.81. Other reported metrics like LV/RV end-diastolic and end-systolic volumes, and LV myocardial mass also showed high ICC values (0.95-0.99), indicating strong correlation with expert analysis, though the results are not intended for stand-alone clinical decision-making.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AI4CMR v1.0's performance vary across different MR scanner vendors (Siemens, GE, Philips) and field strengths (1.5T vs. 3T) beyond the balanced dataset used in the clinical performance assessment?; What specific neural network architecture and AI techniques are employed for the automatic segmentation, and how were they optimized during development using the training and validation datasets?; Given the training dataset was predominantly male (63%) and from a single Siemens acquisition system, what is the confidence in performance for female patients and images from other MR systems not extensively covered in training?; The document states the user is responsible for implementing the user interface; what are the technical integration requirements or guidelines provided to ensure consistent and reliable use of the AI4CMR plug-in across different DICOM viewers?; How does the accuracy of derived metrics (e.g., stroke volume, cardiac output, indexed values), which are simple mathematical derivations, propagate errors from the primary AI-quantified metrics like EDV and ESV, especially when patient data for indexing is missing or inaccurate?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly